Penumbra Confirms $14.5B Acquisition by Boston Scientific in Strong FY25 Annual Report

summarizeResume

This 10-K filing officially confirms the definitive merger agreement for Penumbra to be acquired by Boston Scientific Corporation, a highly significant event that redefines the company's future. While the merger was previously announced, this annual report provides the comprehensive, audited financial context and detailed terms. The strong financial performance for fiscal year 2025, with substantial revenue and net income growth, further underscores the company's value leading into this acquisition. The initiation of a new manufacturing facility in Costa Rica also highlights strategic growth initiatives, now under the umbrella of the acquiring entity. Investors should note the confirmed terms of the acquisition and the solid financial footing Penumbra brings to the deal.

check_boxEvenements cles

• Definitive Merger Agreement Confirmed

  Penumbra entered into a definitive agreement on January 14, 2026, to be acquired by Boston Scientific Corporation for an enterprise value of approximately $14.5 billion, valuing each share at $374. The consideration is approximately 73% cash and 27% Boston Scientific common stock, with the transaction expected to close by the end of 2026, subject to approvals.

• Strong Fiscal Year 2025 Financial Performance

  The company reported a 17.5% increase in revenue to $1,403.7 million for the year ended December 31, 2025, up from $1,194.6 million in 2024. Net income significantly increased to $177.7 million ($4.52 diluted EPS) in 2025, compared to $14.0 million ($0.36 diluted EPS) in 2024.

• Immersive Healthcare Business Exit Completed

  No further impairment or other charges were incurred in 2025 related to the wind-down and exit of the immersive healthcare business, which had resulted in $115.3 million in charges during 2024.

• New Costa Rica Manufacturing Facility Underway

  Penumbra initiated a $58 million project to construct a new manufacturing facility and warehouse in Costa Rica, with $37.3 million in payments made during 2025.

auto_awesomeAnalyse

This 10-K filing officially confirms the definitive merger agreement for Penumbra to be acquired by Boston Scientific Corporation, a highly significant event that redefines the company's future. While the merger was previously announced, this annual report provides the comprehensive, audited financial context and detailed terms. The strong financial performance for fiscal year 2025, with substantial revenue and net income growth, further underscores the company's value leading into this acquisition. The initiation of a new manufacturing facility in Costa Rica also highlights strategic growth initiatives, now under the umbrella of the acquiring entity. Investors should note the confirmed terms of the acquisition and the solid financial footing Penumbra brings to the deal.